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We characterized dopamine toxicity in human neuroblastoma SH-SY5Y cells as a direct effect of dopamine on cell reductive power,
measured as NADH and NADPH cell content. In cell incubations with 100 or 500 μM dopamine, the accumulation of dopamine inside the
cell reached a maximum after 6 h. The decrease in cell viability was 40% and 75%, respectively, after 24 h, and was not altered by MAO
inhibition with tranylcypromine. Dopamine was metabolized to DOPAC by mitochondrial MAO and, at 500 μM concentration, significantly
reduced mitochondrial potential and oxygen consumption. This DA concentration caused only a slight increase in cell peroxidation in the
absence of Fe(III), but a dramatic decrease in NADH and NADPH cell content and a concomitant decrease in total cell NAD(P)H/NAD(P)+
and GSH/GSSG and in mitochondrial NADH/NAD+ ratios. Dopaminechrome, a product of dopamine oxidation, was found to be a MAO-A
inhibitor and a strong oxidizer of NADH and NADPH in a cell-free system. We conclude that dopamine may affect NADH and NADPH
oxidation directly. When the intracellular concentrations of NAD(P)H and oxidized dopamine are similar, NAD(P)H triggers a redox cycle
with dopamine that leads to its own consumption. The time-course of NADH and NADPH oxidation by dopamine was assessed in cell-free
assays: NAD(P)H concentration decreased at the same time as dopamine oxidation advanced. The break in cell redox equilibrium, not
excluding the involvement of free oxygen radicals, could be sufficient to explain the toxicity of dopamine in dopaminergic neurons.
© 2006 Elsevier B.V. All rights reserved.Keywords: Dopamine; SH-SY5Y cell; NADH; NADPH; NAD(P)H/NAD(P)+1. Introduction
Although dopamine (DA) is the main neurotransmitter of the
nigrostriatal pathway and its loss is the main neurochemical
parameter in Parkinson's disease, DA itself has often been
suspected of having a function in the genesis of dopaminergic
neurodegeneration. The potential toxicity of DA has been
studied and described in several cell models, such as chick
embryo sympathetic neurons [61], primary nigral, forebrain and
striatal rat cultures [26,39,41], SH-SY5Y human neuroblastoma
cells [34] and PC12 cells [29], with the aim of clarifying the
apparent "dopamine paradox" [11,55].⁎ Corresponding author. Tel.: +34 93 403 90 94; fax: +34 93 402 42 68.
E-mail address: sambrosio@ub.edu (S. Ambrosio).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.02.003It is commonly assumed that DA triggers cell oxidative stress by
its own enzymatic oxidation bymonoamine oxidase (MAO) or, like
6-OHDA toxicity, through its non-enzymatic, pH-dependent
autoxidation. In both cases it generates H2O2, which causes cell
oxidative stress, and increases lipid and protein peroxidation [7,33].
Dihydroxyphenylacetic acid (DOPAC) is the main product of
MAO metabolism, and DA autoxidation gives different oxidized
products with at least 4 electrochemical peaks between 0.21 and
0.29 V at pH 7 (increasing 65 mV/pH unit [16]), among them
dopaminequinone, dopaminechrome and products of condensation,
which finally yield neuromelanin [17]. Quinones may react with
cysteine residues, modify protein structures [35] and induce DNA-
damage [54] and thus apoptosis [23]. However, it has also been
reported that, due to its redox properties, DAmay act as a reducing/
antioxidant agent and so, at least at low concentrations, have a
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oxidative stress caused by DA may be strongly linked to the DA
concentrations inside the cell and to the collateral effects on
compounds with a potentially higher reduction potential.
Several authors, using isolated mitochondria, describe the
effect of DA on mitochondrial respiration [6,8,21,36,42], or a
strengthening of the MPP+ effect by DA [12]. Although the
effect of DA beyond its action as a neurotransmitter has often
been questioned and even considered an artifact [14],
experience shows that cells with high DA concentrations,
such as dopaminergic neurons, are highly vulnerable to
degeneration. The DA paradox is the subject of a number of
studies, which have lead to the hypothesis that an imbalance
between cytosolic and vesicular DA switches on a process that
leads to neuron degeneration [5].
Human neuroblastoma SH-SY5Y cells can be used to study
DA cytotoxicity due to their dopaminergic characteristics [44].
Apoptotic [30], necrotic and autophagic [21] cell death has been
described in these cells after incubation with DA. At present, all
the effects described by DA on SH-SY5Y cells are prevented by
antioxidants of intracellular action [21], which indicates that the
damage caused by DA is mediated by its oxidation or by its
oxidized products.
The mechanisms of degeneration of DA neurons in the
substantia nigra of Parkinson's disease patients have not yet
been shown conclusively. Neurons dying by apoptosis,
autophagy or non-defined death forms have been described
[2]. We present data indicating that non-vesiculated DA, when it
achieves high intracellular concentrations, may overcome the
antioxidant capacity of the cell, thus directly interfering in cell
redox potential and inducing cell damage.
2. Material and methods
2.1. Cell Culture
SH-SY5Y cells (kindly provided by Dr. J. Comella, University of Lleida,
Spain) were grown in Dulbecco's Modified Eagle Medium (DMEM, Gibco
BRL, Paisley, UK), supplemented with 10% fetal bovine serum (Gibco BRL),
100 U/ml penicillin and 100 μg/ml streptomycin. Cells were maintained in a
humidified 10% CO2 atmosphere at 37 °C. Experiments were performed in 6- or
12-well culture plates at ~80% cell confluence.
2.2. Compounds
Dopamine (DA) was purchased from Sigma (St. Louis, MO) and added to
the medium at a final concentration of 100 or 500 μM. Dihydroxyphenylacetic
acid (DOPAC), tert-butylhydroperoxide (tBOOH), reduced (GSH) and oxidized
(GSSG) glutathione, NADH and NADPH, and tranylcypromine (TCP) were
from Sigma. FeCl3 was from Merck. Dopaminechrome (DAchr) was prepared
from DAwith sodium periodate (20 mM, Sigma) in a 20 mM Tris buffer at pH
6.8 and room temperature, following the procedure described in [3]. [7,8-3H]-
DA and [3H]-thymidine were from Amersham Biosciences, GmbH Europe
(Barcelona, Spain). Proteins were determined by the BCA™ assay (Pierce,
Rockford, IL). All the reagents were of analytical grade except for HPLC
analysis, in which reagents were of HPLC grade.
2.3. DA-uptake
Cells were incubated in 1 ml of DMEMwith different final concentrations of
DA (0, 50, 100, 250, 500 μM), containing 10 nCi/μmol of [7,8-3H]-DA, fordifferent times up to 24 h. To measure DAchr uptake, the radio-labeled DAwas
previously oxidized as indicated above. The cells were washed three times in
DMEM, after which no significant radioactivity was detected in the medium,
and lysed with 0.5 ml of 1% SDS. Radioactivity was determined by liquid
scintillation counting as cpm per mg of protein and values were corrected to be
expressed as pmol/mg prot.
2.4. Viability and proliferation assays
2.4.1. [3H]Thymidine incorporation
Cells were incubated in DMEM containing [3H]thymidine (1 μCi/ml; 1 mM)
and 0, 100 or 500 μM DA. After different times, cultures were washed in
phosphate buffered saline (PBS) and the cells were lysed with trichloroacetic
acid (TCA) for 30 min at 4 °C. TCAwas then removed and the cell lysates were
washed in ethanol and extracted in 0.5 ml of 2% Na2CO3, 0.1 M NaOH, 1%
SDS. Tritium incorporation was determined by liquid scintillation counting.
2.4.2. Acridine orange
Cell viability was determined with acridine orange/ethidium bromide (1:1)
by microscopy fluorescence. Living cells incorporate acridine and become
green, whereas damaged or dead cells are stained orange-red by ethidium
bromide.
2.4.3. MTT
3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; RBI)
is converted in living cells by reduction into insoluble formazan, whose amount
is proportional to the number of viable cells. Cells (5×105) were incubated for
2 h at 37 °C with 0.5 mg/ml MTT. The cells were washed and lysed with an
equal volume of isopropanol/HCl (1 M) (24:1). Reduced MTTwas measured at
550 nm in a 96-microtiter plate.
2.5. Peroxidation measurements
After incubation in a range of conditions, the cell were washed twice in
HSSB (NaCl 135 mM, KCl 5 mM, CaCl2 1.8 mM, MgSO4 0.62 mM, HEPES
10 mM) and incubated with 10 μM 2′,7′-dichlorofluorescein diacetate (DCFH-
DA, Sigma) for 30 min. Cells were washed twice in HSSB, and cellular
fluorescence intensity was measured in a Microtiter Fluorescence Plate Reader
(Biorad) at 485 nm excitation and 538 nm emission.
2.6. Mitochondrial potential
Changes in mitochondrial function were determined by analyzing the
mitochondrial potential (ΔΨm) by cytometry. 10
6 cells were incubated with
4 μg/ml JC-1 (Molecular Probes) for 45 min at 37 °C in DMEM without serum.
Cells were scored using a FACScalibur flow cytometer and data were analyzed
on Cellquest Pro software by measurement of both green (530±15 nm, FL-1)
and orange (585±21 nm, FL-2) JC-1 fluorescence. The loss in ΔΨm is seen as a
shift to lower JC-1 orange fluorescence accompanied by an increase in JC-1
green fluorescence. At least 10,000 events were collected per sample.
2.7. Oxygen consumption
After DA treatment, SH-SY5Y cultures were rinsed twice with PBS, trypsinized
and counted. Cell suspensions were adjusted to 105 cells/ml with DMEM. Cell
respiration was measured at 37 °C and 750 rpm stirring speed in an Oxygraph high-
resolution respirometer with DatLab software for data acquisition and analysis
(Oroboros, Innsbruck, Austria). Extra-mitochondrial oxygen consumption was
measured on addition of 20μMantimycinA. Results were standardized in relation to
the actual protein content in the measuring chambers.
2.8. DA and DOPAC quantification
Cells were lysed with 0.4 M HClO4 and centrifuged for 10 min (12,000×g).
DA and DOPAC were determined in the supernatants (after filtering with 0.4 μm
pore-sizeMillipore HV filters) by HPLC (LKB-Pharmacia) with electrochemical
detection (Coulochem II, ESA). A nucleosil C-18 reverse-phase column (5 μm,
Fig. 1. (A) DA accumulation in the cells for up to 24 h of incubation with
100 μM or 500 μM DA measured by [3H]-DA uptake. (B) [3H]-DA and [3H]-
DAchr uptake by SH-SY5Y cells after 24-h incubation.
Fig. 2. Time course of [3H]thymidine incorporation in control cells (CT) and
in dopamine-treated (100 μM and 500 μM DA) cells. *P<0.001 compared
with CT.
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acetate, 25 mM citric acid, 0.7 mM octanesulfonic acid and 10% methanol at pH
4.1, filtered with 0.2 μm pore-size Millipore filters and degassed. A dual
electrochemical detector was used with E1=+50 mV and E2=+300 mV at the
analytical cell.
2.9. MAO activity
MAO-A activity was determined radiochemically, with 14C-labeled
substrate as previously described [18]. Briefly, mitochondrial fractions were
prepared by differential centrifuging [20] and pre-incubated for 30 min with
different Dopaminochrome concentrations (10−3−10−10 M). Afterwards, the pre-
treated enzymes were incubated at 37 °C for 15 min with 100 μM [14C]-5-HT
(0.5 mCi mmol−1), the MAO-A-specific substrate. Reactions were stopped by
the addition of 100 μl of 2 M citric acid. Radioactive aldehyde products were
extracted into toluene/ethyl acetate (1:1) containing 0.6% 2,5-diphenyloxazole
(w/v) before liquid scintillation counting. Total activity was determined in the
same assay conditions without inhibitor and the remaining MAO-A activity was
expressed as percentage of the total activity. The IC50 value of DAchr as MAO-
A inhibitor was calculated with the Graph-Pad Prism program.
2.10. Redox parameters
2.10.1. GSH/GSSG
We used a modified OPA assay procedure [51]. 4×105 cells were plated
and, after various treatments, were washed twice in ice-cold PBS. Cells were
lysed with 1 ml of lysis buffer (20 mM HCl, 5 mM DTPA, 10 mM ascorbic
acid and 5% HClO4) and the suspensions were centrifuged at 12,000×g for
10 min at 4 °C. The resulting supernatant solutions were centrifuged again for
5 min through a 0.45-μm microcentrifuge filter (Millipore, Bedford, MA,USA). The filtered supernatants were used to determine GSH and GSSG
levels by fluorescence (Shimadzu spectrofluorimeter) after o-phthaldialdehyde
(OPA) derivatization.
2.10.2. Cellular NADH and NADPH
NADH and NADPH total cell content was determined by HPLC. Cells were
extracted in alkaline medium to avoid the oxidation of NAD(P)H with 0.5%
Nonidet P-40 buffer containing KOH at pH 9.0. The cell lysates were
centrifuged at 3,000 rpm for 5 min at 4 °C and the supernatants immediately
filtered through 0.4 μm pore-size Millipore HV filters. Reverse-phase HPLC
was performed with a Nucleosyl-C18 (5 μm, Tracer) column on a Pharmacia-
LKB HPLC. The mobile phase was 50 mM sodium acetate (pH 8.0 with KOH)
and 15% methanol at 1 ml/min flow rate. NADH and NADPH peaks were
monitored with a UV detector (Pharmacia-LKB) at 340 nm.
The totalNAD+ and the cytoplasmNAD+ content were determined in hydrazine-
glycine buffer (0.3 M hydrazine sulfate, 0.87 M glycine, 0.19 mM EDTA pH 9.5),
with 12 U/ml LDH, using 2 mM lactate as a substrate, after acidic lysis of the cells
with 3%HClO4, centrifugation and neutralization of the supernatant, or in a cytosolic
fraction after separation of membranes and organelles. The cytosolic fraction was
obtained from trypsinized cells lysed with a buffer containing: 25 mMTris, 200 mM
sucrose, 1 mM EDTA, 0.05% digitonin, 1 mM DTT, 0.1 mM PMSF, 1 μg/ml of
leupeptin, pepstatin, aprotinin, benzamidine. The cells homogenates were
centrifuged at 15,700×g and the supernatants were collected as cytosolic fractions.
Cytoplasmic NADH was deduced from cytoplasmic NAD+ and the cytoplasmic.
[NADH]/[NAD+] ratio. The difference between total and cytoplasm contents, both
relating to the total protein cell content, was used to estimate NAD+ and NADH
mitochondrial contents.
2.10.3. Pyruvate/lactate and NADH/NAD+ ratio measurements in cells
Extracts were obtained by washing the cells twice in phosphate-buffered saline
(PBS) and then scraping the cell layer in 0.1ml of PBSwith 0.1ml ofHClO4 at 6%. It
was then centrifuged at 13,000 rpm for 10 min at 4 °C. Supernatant was neutralized
with 3MNaOH.Pyruvate in 100μl of extractwasmeasuredwith 100μl of a reaction
mixture containing 40 μM NADH, 0.3 U/ml of lactate dehydrogenase (LDH) in
50 mM imidazole buffer, pH 7.0. After 15 min at room temperature, 40 μl of 0.1 M
HClwas added and themixture heated to 60 °C for 15min. 75μl of 12MNaOHwas
added and the mixture heated again to 60 °C for 15 min. The fluorescence of the
mixturewasmeasuredwith a Fluorimeter at 355 nm excitation and 440 nm emission.
Lactate (Lac) concentration was measured by a procedure described elsewhere [25].
Cytoplasm [NADH]/[NAD+] was calculated by the formula [NADH]/[NAD+]=
[Lac]/[Pyr]×KLDH, where KLDH is 1.1×10
− 4 at pH 7.0 [4].
2.11. In vitro NAD(P)H and DA oxidation
NADH and NADPH and oxidation were measured in vitro in cell-free
solutions containing 100 μM NADH or NADPH and varying DA or DAchr
concentrations, in 0.1 M PBS buffer (pH 7.4) and in 96-well microtiter plates, by
following the absorbance of these solutions at 340 nm. DA oxidation was
analyzed in the same solutions at 492 nm. The effect of 5 mMGSH, 1 mM FeCl3
(Fe(III)) or both was also assessed by this procedure.
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The significances of differences between groups were analyzed by ANOVA
and the Scheffé test.3. Results
The study of the uptake of [7,8-3H] DA by the cell revealed
that DA, at concentrations of 100 and 500 μM (DA-100 and
DA-500), accumulates in the cell in a fast and concentration-Fig. 3. (A) Viability of controls and 100 μM (DA-100)- or 500 μM (DA-500)-treated
cells) after 24 h. Scale bar=100 μm. (B) Percentage of living (green) cells deduced
100 μM and 500 μM DA. The gray lines indicate the effect of 1 mM tranylcypromi
control non-DA-treated cells. D) MTT cell viability at 24 h in cells incubated for diffe
samples. *P<0.05, **P<0.01, ***P<0.001 compared with controls (time 0), #P<0.
figure legend, the reader is referred to the web version of this article.)dependent manner, reaching an intracellular maximum after
about 6 h (Fig. 1A). The concentrations of DA, or derived
compounds, found inside the cell after 24 h were approximately
80 μM and 270 μM for respectively DA-100 and DA-500
(taking protein and water content as 15% and 70% of cell
weight). The amount of autoxidized DA in a culture medium at
37 °C was determined in vitro by HPLC and electrochemical
detection measuring the decrease in total DA. The decrease was
linear over time and was established at 15±1% after 24 h, so
that the real extracellular reduced DA concentrations were 85cells with acridine orange (green, living cells) and ethidium bromide (red, dying
from three separate experiments. (C) Time course of MTT cell viability with
ne (TCP). The values are expressed in each time as the % of the corresponding
rent times with 500 μMDA. The values are expressed as the mean±S.E.M. of 4
05 compared with DA-100. (For interpretation of the references to colour in this
Fig. 4. Inhibition of MAO-A activity by DAchr. Rat liver mitochondrial
fraction was pre-incubated in presence of different concentrations of DAchr
(10−10–10−3 M) for 30 min at 37 °C. MAO-A activity was measured at
100 μM [14C]-5-hydroxytryptamine as substrate. The IC50 value was
4.9 × 10−5 M. Each point represents the mean value±S.E.M. (n=3).
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Labeled DAchr, the main autoxidation product of DA, was
detected inside the cell only when 500 μM concentrations were
used, but not at concentrations under 100 μM, which could be
achieved by extracellular DA autoxidation (Fig. 1B).
In order to establish how the intracellular accumulation of
DA affects cell proliferation and viability, these parameters
were measured by different procedures. Cell proliferation was
studied by [3H]-thymidine incorporation in a starting number of
30,000 cells with or without DA up to 24 h of incubation. Fig. 2
shows that cell proliferation was not affected by DA-100, but
was dramatically decreased by DA-500. The viability of SH-
SY5Y was detected by two different procedures. Fluorescence
microscopy with orange acridine plus ethidium bromide also
showed no significant damage with DA-100, but 56% of cells
incubated with DA-500 were unviable after 24 h (Fig. 3A, B).
However, the viability of the cell cultures, measured by the
MTT procedure, was reduced to 60% and 25% of un-treated
controls after 24 h incubation with, respectively, DA-100 and
DA-500 (Fig. 3C). The addition of a non-specific MAO
inhibitor, 1 mM tranylcypromine (TCP) [12], did not alter the
effect of DA-500 and reduced by 10% the effect of DA-100.
The effect of DA-500, measured at 24 h, was reversible if DA
was removed after 1 h, but not if DA was removed after 3 h or
more (Fig. 3D).
The rate of enzymatic metabolization of intracellular DA by
mitochondrial MAO was assessed by measuring the content of
its main metabolite, DOPAC. DA-100 was metabolized to
DOPAC after 24 h, providing a DOPAC concentration of about
600 pmol/mg prot. DA content in non-treated controls was
about 3 pmol/mg prot (similar results in neuroblastoma cells
were reported by other authors [40,44]). As indicated in Table 1,
the DOPAC/DA ratio was similar in controls and DA-100, but
very much lower with DA-500. The increase in DAwas not due
to extracellular DA, because the medium was washed until no
DA was detected. Thus, this increase could indicate MAO
saturation, inhibition or both.
Considering that intracellular DA may also be oxidized non-
enzymatically to DAchr, we examined the effect of DAchr on
MAO activity. For this purpose MAO-A activity (the main
isoform described in SH-SY5Y cells [59]) was measured using
isolated mitochondria and serotonin as substrate in the presence
of different concentrations of DAchr. MAO-A activity was
inhibited by DAchr, with an IC50 49 μM (Fig. 4).
The mitochondrial activity was assessed by measuring the
oxygen consumption and membrane potential. Cell oxygen
consumption, determined by a respirometer, was reduced toTable 1
DOPAC and DA content in SH-SY5Y cells after treatment with 100 or 500 μM
dopamine (pmol/mg prot)
CT DA-100 DA-500
DOPAC 45±8 634±80*** 385±32***,#
DA 3±0.5 47±3*** 1285±171###
DOPAC/DA 15.1±5.0 13.5±1.2 0.3±0.06###
The values are the mean±S.E.M. of 4 experiments. *,#P<0.05, ***,###P < 0.001
compared with controls (*) or DA-100 (#).60% after 6 h and to less than 20% after 24 h of incubation with
DA-500 (Fig. 5). No significant changes were found with DA-
100. Mitochondrial membrane potential (Δψm) was also
significantly reduced to 40% after 24 h of DA-500 incubation
(Fig. 6), as determined by flow cytometry using JC-1 as
fluorescent marker for mitochondrial function.
The autoxidation of DA and the reduction of mitochondrial
activity could lead to an increase in H2O2 production and
consequently to oxidative stress. The oxidative stress caused by
DA was assessed by DCFH fluorescence, essentially a
measurement of cell peroxidation. It was compared with the
effect of a strong peroxidative agent, tert-butylhydroperoxide
(tBOOH, 100 μM), which increased fluorescence intensity
nearly 3-fold in 2 h, before significantly reducing cell viability
(at longer time-periods this tBOOH concentration was very
cytotoxic). In this short period, DA-500 increased DCFH
fluorescence by only 50%, unless 1 mM Fe(III) was added to
the medium as a DA oxidation catalyser. In addition, DA acted
as an antioxidant against tBOOH, blocking its effect (Fig. 7A).
Up to 24 h DA-500 alone increased significantly, but not
dramatically, cell peroxidation (nearly 75%), whereas theFig. 5. Oxygen consumption measured with a respirometer in cells resuspended
after being treated for 6 or 24 h with 0, 100, 500 μM DA. The values are
expressed as the mean±S.E.M. of 4 samples. Significance was *P<0.05,
**P<0.01, ***P<0.001 compared with controls.
Fig. 6. Cell cytometry distribution of cells labeled with JC-1 as a marker for mitochondrial potential (ΔΨm). Values are the % of JC-1 in its aggregated form (polarized
mitochondria) with 100 and 500 μM DA. The values are the mean±S.E.M. of 3 experiments. Significance was **P<0.01 compared with controls.
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(Fig. 7B). Fe(III) alone, unlike Fe(II), had no effect on DCFH
values (not shown). The cell viability at 24 h equally decreased
with DA and with DA plus 1 mM Fe(III) (Fig. 7C).
All these results, especially the decrease in cell viability
measured by MTT, which was greater than the decrease
assessed by other procedures (Figs. 2–4), suggested that
redox cell equilibrium, in terms of NADH and NADPH
(NAD(P)H), should be studied after DA treatment. In cell
cultures with DA-500, both NADPH and NADH contents,
determined by HPLC, dropped significantly, to 75% and 50%
respectively, after 6 h of incubation and dropped severely to
50% and under 20% after 24 h. This effect was maintained even
when DA was removed after 6 h. NADH and NADPH content
also fell significantly by 20% after 24 h of incubation with DA-
100 (Fig. 8). The reductive power of the cell is given mainly by
the ratio between reduced NADH and oxidized NAD+ forms in
the mitochondria and, to a lesser extent, in the cytoplasm. The
ratio between NADH and NAD+ in cell cytoplasm was
determined from the lactate/pyruvate measurements (Table 2)
[4,10]. The ratio [NADPH]/[NADP+] is usually considered to
be proportional to the ratio between reduced (GSH) and
oxidized (GSSG) forms of glutathione [1]. As Table 2 shows,
both DA-100 and DA-500 significantly decreased the [GSH]/
[GSSG] ratio after 24 h. This reduction was due mainly to an
increase in the oxidized form GSSG, since the reduced form
GSH decreased very slightly. NAD+ cytoplasm and total
content were measured spectrophotometrically. As the differ-
ence between total and cytoplasm NAD+ (both related to the
total protein content) should correspond mainly to mitochon-
drial NAD+ (nuclear NAD+ content is comparatively low), wededuced the mitochondrial ratio [NADH]/[NAD+], as indicated
in Table 3. Cytoplasmic [NADH]/[NAD+] doubled, whereas
mitochondrial [NADH]/[NAD+] dropped to 20% after 24 h with
DA-500, but cytoplasmic NADH represents only about 1% of
total NADH [10].
The effect of DA on NAD(P)H oxidation was studied in a
cell-free system by analysis of the disappearance of NAD(P)H
at 340 nm and the oxidation of DA at 492 nm. Very similar
results were obtained with NADH and NADPH (not shown).
The NAD(P)H content (100 μM) decreased rapidly in the
presence of DA. The loss of NAD(P)H was faster when
incubated with DAchr instead of DA (Fig. 9A). The effect of
500 μM DA increased with 1 mM Fe(III) and was counteracted
by 5 mM GSH, whereas the addition of both Fe(III) and GSH
gave only partial protection (Fig. 9B). The oxidation of DA
proceeded slowly when NAD(P)H was present in the medium.
DA oxidation abruptly increased as NAD(P)H decreased (Fig.
9C). The antioxidant effect of NADH on DA oxidation (492 nm
reading) was confirmed by incubating 500 μM DAwith 5 mM
NADH at room temperature (not shown).
4. Discussion
The cytotoxicity of DA is described basically at the
extracellular concentrations of 100 and 500 μM (DA-100 and
DA-500). These concentrations could be considered above the
physiological range, since DA extracellular concentrations in
substantia nigra or striatum are far lower, of the order of nM, as
microdialysis procedures show [49]. The striatal concentration
of DA is, however, estimated to be about 70 μM, whereas the
dopaminergic concentration in the neuronal endings is of the
Fig. 8. (A) NADH and (B) NADPH content in alkaline cell homogenates after
incubation with 100 or 500 μM DA. Dashed lines indicate the values of
NADH and NADPH when DA-500 was removed after 6 h. Each point is the
mean±S.E.M. of 4 different samples. Values in non-treated cells were not
modified at different times. Significance was *P<0.05, **P<0.01,
***P<0.001 compared with control non-treated cells.
Table 2
Lactate, pyruvate, GSH and GSSG content
(A) Lactate (Lac), Pyruvate (Pyr) and Lac/Pyr ratio in SH-SY5Y cells 6 and
24 h after treatment with 100 and 500 μM dopamine
Lac (nmol/mg prot) Pyr (nmol/mg prot) Lac/Pyr
6 h CT 624.5±29.3 33.1±3.7 18.9±3.1
DA-100 682.8±44.7 25.2±1.7 27.0±2.2*
DA-500 702.9±20.4 28.3±1.5 24.8±1.8*
24 h CT 389.1±25.8 28.5±1.6 13.6±1.1
DA-100 419.1±96.5 24.9±1.0 16.8±4.2
DA-500 273.4±21.9* 7.7±0.3* 35.5±2.8*
(B) GSH, GSSG content and GSH/GSSG ratio in SH-SY5Y cells 6 h and
24 h after treatment with 100 and 500 μM dopamine
GSH (nmol/mg prot) GSSG (nmol/mg prot) GSH/GSSG
CT 29.4±6.2 2.9±0.8 10.2±0.4
6 h DA-100 28.5±3.7 3.4±1.0 8.3±0.8
DA-500 20.6±3.2* 3.2±1.0 6.5±0.9*
24h CT 25.9±5.8 2.4±0.5 10.7±1.3
DA-100 25.7±5.1 5.2±0.5* 4.9±4.4*
DA-500 21.7±5.0* 7.0±0.3* 3.1±0.4*
Values are the mean±S.E.M. for 3 different experiments. *P<0.05 versus
controls (CT).
Fig. 7. (A) DCFH fluorescence as a measurement of cell oxidative stress up to 2 h
with 500 μMDA, 100 μM tBOOH andDA-500 plus tBOOH or 1mMFeCl3. (B)
DCFH fluorescence up to 24 h in control, DA-500 and DA-500+FeCl3. No
significant difference in fluorescence was found between control and DA-100 or
FeCl3 alone incubations. (C) Cell viability byMTTat 24 h with 1 mMFeCl3. The
values are the mean±S.E.M. for 3 measurements. Significance was *P<0.05,
**P<0.01, ***P<0.001 compared with non-treated control cells.
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during the phasic release has also been established as being of
the order of mM [58]. The purpose of this study was to describe
the effects of non-vesiculated intracellular DA in a range of
concentrations that could be achieved intracellularly if DAwas
not efficiently stored in vesicles or if vesicles were disrupted.
We show that DA, at high enough concentrations, enters and
accumulates in SH-SY5Y cells, as has been reported for other
neuroblastoma cell lines [48]. This entry is probably mediated
by transporters with low affinity for DA (for instance,
noradrenaline transporter [50]) or by non-receptor mediated
endocytosis [43], since the expression of the DA transporter
(DAT) [37] and the rate of transport at saturating concentrations
(10 μM DA) are very low in these cells (about 2 pmol/mg/min
[28]). Moreover, DAT inhibitors [21] or inhibitors of the organic
cation transporter (OCT, results not shown) only partially
prevent the effects of DA.The highest DA concentration (DA-500) had antiprolifera-
tive and cytotoxic effects on SH-SY5Y cells (its effect on cell
differentiation is currently being explored in our lab), which
corroborates results of other authors [46]. This effect is not
receptor-mediated, because the SH-SY5Y cells express DA
Table 3
NAD+, NADH content (pmol/mg prot) and [NADH]/[NAD+] ratio in the total
cell, cytoplasm and mitochondria in controls and 24 h after treatment with 100 or
500 μM dopamine (DA-100 and DA-500)
CT DA100 DA500
NADHT 300±25 240±22 ⁎ 60±12 ⁎⁎
NAD+T 2860±370 2650±360 3020±630
(NADH/NAD+)T 0.105±0.013 0.091±0.015 0.020±0.002 ⁎⁎⁎
NADHcyt 1.30±0.12 1.05±0.10 3.70±0.44 ⁎
NAD+cyt 870±122 570±230 950±250
(NADH/NAD+)cyt 0.0015±0.0001 0.0017±0.0001 0.0039±0.0001 ⁎
NADHmit 298±30 239±25 56±6 ⁎⁎
NAD+mit 1990±130 2080±173 2070±190
(NADH/NAD+)mit 0.15±0.02 0.11±0.02 0.03±0.00 ⁎⁎
The results are the mean±S.E.M. for 3 different experiments.
⁎ P<0.05.
⁎⁎ P<0.001 compared with controls (CT).
⁎⁎⁎ P<0.01.
Fig. 9. Experiments in 0.1M PBS buffered cell-free system. (A) Decrease of
absorbance at 340nm in a solution containing 100μM NADH alone (CT, white
circles), and 100μMNADH plus 100μMDA (black circles), 500μMDA (black
squares), 100μM DAchr (gray circles) or 500μM DAchr (gray squares); (B)
Decrease of absorbance at 340 nm in a solution containing 100μM NADH
alone (CT, white circles), and 100μM NADH plus 500μM DA+5mM
GSH (white squares), 500μM DA+1mM FeCl3 (black squares), 500μM
DA+5mM GSH+1mM FeCl3 (black rhombs). (C) Increase in absorbance
at 492nm (dopamine oxidation) of 100μM DA (white circles), 500μM
DA (white squares), 100μM DA+100μM NADH (black circles), 500μM
DA+100μM NADH (black squares), 500μM DA+5mM GSH (white
triangles) and 500μM DA+1mM FeCl3 (gray squares).
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lished result from our group). DA-100 was not sufficient in our
model to decrease cell proliferation or viability, respectively
measured by [3H]-thymidine uptake and acridine orange plus
ethidium bromide, but it did decrease MTT measurements by
40% [21,34]. The discrepancy between these results may be
attributable to the differences in the procedures. Whereas
ethidium bromide does not dye the cell while membrane
integrity is preserved, MTT is a very sensitive parameter of cell
reductive power, reflecting the mitochondrial function and also
the redox status of the cytoplasm [9]. Results by MTT probably
overestimate the effect of DA on cell viability, indicating overall
redox alteration even when cell viability is still preserved, as
with DA-100.
The effect of DA on cell viability can be attributed mainly to
the DA accumulated inside the cell. Although a direct effect of
extracellular DA on membrane integrity cannot be ruled out, we
think it irrelevant for several reasons: higher membrane lipid
peroxidation reflected in DCFH measurements would be
expected; DA maintained its effect on cell viability at 24 h
even when it was removed after 3 h of incubation; the
extracellular H2O2 concentrations described in cell incubations
with 500 μMDA are about 5 μM [24], which is not toxic for SH-
SY5Y cells (results not shown). In addition, we have shown that
the incorporation to the medium of an extracellular antioxidant
such as catalase does not protect against DA toxicity [21,23].
The inhibition of MAO activity with TCP has only a slight
protective effect (10%) at DA-100, which exonerates this as the
main mechanism responsible for DA toxicity. Assuming that the
first step in DA-mediated toxicity is non-enzymatic, the
increased peroxidation caused by DA-500 was relatively
small compared with that caused by 100 μM of tBOOH, and
it increased dramatically only when 1 mM Fe(III) was present in
the medium as a DA oxidation catalyser. However, the addition
of iron did not increase the damage caused by DA on cell
viability, indicating that the increase of peroxidation is not the
main factor responsible for cell death. Some authors have even
reported that the addition of iron to the cell cultures may protectagainst DA toxicity [27]. However, Fe(III) increases the rate of
DA oxidation in the extracellular space (Fe(III), contrarily to
Fe(II) does not enter easily into the cell). It may thus decrease
the DA uptake by the cell, since the uptake of DAchr is very
low, as we show in Fig. 1. In addition, the DCFH increase
caused by tBOOH is greatly reduced by DA, confirming that
DA plays an antioxidant role in the presence of highly oxidant
compounds [53].
MAO actively metabolizes DA-100, giving approximate
intracellular concentrations for DOPAC and DA at 24 h that can
be deduced from Table 1 as, respectively, 90 and 7 μM. At this
concentration, the cell antioxidant mechanism may be enough
to minimize the toxic effect of DA. With DA-500 treatment a
large amount of DA remains unmetabolized (about 160 μM),
indicating saturation or inhibition of MAO. As we showed here,
one of the main products of DA autoxidation, DAchr, strongly
Fig. 10. Proposed diagram for dopamine alterations in NAD(P)H/NA(P) + redox
equilibrium. DA oxidizes with O2, giving H2O2 in a reaction catalyzed by
Fe(III). The oxidized DA may be further reduced by NADH or NADPH,
giving a cycle that consumes NAD(P)H and increases the levels of oxidized
glutathione (GSSG).
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cells [57]. The IC50 of 49 μM for MAO-A inhibition by DAchr
might be achieved in the mitochondria after 24 h of DA-500
incubation. MAO inhibition contributes to free DA accumula-
tion, but prevents enzymatic H2O2 production and may reduce
oxidative stress and enhance cell viability, as assessed using
DA-100 plus TCP.
In previous studies [21,22] we concluded that DA-500
induced cytoplasmic damage, reflected by grp-78 induction and
the presence of numerous autophagic processes, while the
plasmatic and nuclear membranes were preserved. We found no
staining or morphological evidence of mitochondrial alterations
[21]. However, the more precise measurements described in the
present study now indicate that DA does alter normal
mitochondria function. The effect of DA goes beyond MAO
inhibition. Cell oxygen consumption was reduced to 20% and
the mitochondrial potential was reduced to 50% by DA-500
after 24 h. DA has already been described elsewhere as reducing
oxygen consumption in free mitochondria suspensions, with a
bypass of electrons from complex I to DAchr being one of the
mechanisms involved [6,19,62]. It is worth remarking that DA
is much more easily oxidized in a slightly basic medium, like
that found in the mitochondrial matrix (pH 7.9–8.0).
NADH and NADPH measurements indicate that DA-500
significantly decreases the cell reductive power (as already
suggested by MTT assays). This effect was maintained at 24 h
even if DA was removed after 6 h, indicating that intracellular
DA caused permanent changes. The lack of availability of H
supply from NADH mainly affected mitochondria, causing a
hypoxic-like condition and a decrease in aerobic ATP
production [6]. As in hypoxia, anaerobic glycolysis increases,
as reflected in [lactate]/[pyruvate] and [NADH]/[NAD+]
cytoplasm ratios [4,10]. However, the pyruvate concentration
drops significantly in DA-500 treatment, indicating that
pyruvate is probably still used in the mitochondria to
compensate for unsuccessful NADH consumption. The addition
of 1 mM of either pyruvate or lactate did not counteract the loss
of viability (not shown). In the case of NADPH, the cytoplasmic
and mitochondrial concentrations are usually similar, and the
main source is the pentose phosphate pathway, which is not
increased under hypoxic conditions.
All the intracellular antioxidant systems play a decisive role
in DA oxidation and toxicity. In fact, ascorbic acid and N-
acetylcysteine, at concentrations high enough to increase their
intracellular content, prevent DA toxicity [21]. We still have no
clear explanation as to why cell GSH does not prevent DA
toxicity. The presence of a DA oxidation catalyst, such as 1 mM
Fe(III), increased DA oxidation and the fall in NAD(P)H and
partially counteracted GSH antioxidant action. Such a high
concentration of iron is indeed found in substantia nigra [60].
Moreover, the antioxidant action of GSH depends on the
[GSH]/[GSSG] ratio. In a cell culture with DA-100 or DA-500,
the ratio [GSH]/[GSSG] decreases from 10 to 6 and 4,
respectively. This is mainly due to an accumulation of oxidized
GSSG, whereas synthesis of the reduced form GSH, which
could be decreased by NADP+ accumulation and by covalent
trapping by dopaminequinone, is up-regulated, at least withDA-100 [23]. The [GSH]/[GSSG] ratio is usually assumed to be
indicative of the [NADPH]/[NADP+] ratio, because: 2GSH+2
NADP+↔GSSG+2 NADPH, in a reaction catalyzed by
glutathione peroxidase to give GSSG and by glutathione
reductase to give GSH. It can be assumed that the ratio
[NADPH]/[NADP+] decreased by half after 24 h of DA
treatment. This may alter the entire mechanism, depending on
NADPH in the cytoplasm, i.e., NADPH oxidase, NADPH
diaphorases, NADPH-dependent H+-pumps of endoplasmic
reticulum and lysosomes.
The reduction potential for the conversion of DA to
dopaminequinone has been established as E°=−0.240 V [52].
The reduction potentials of NADH and NADPH are, respec-
tively, E°=−0.320 and −0.322 V. Given these values and
considering that NADH concentrations (between 50 and
100 μM) are similar to or lower than DA intracellular
concentrations after the treatment, it was assessed in a cell-free
buffered system that DA-100 and DA-500 oxidize equimolar
NAD(P)H concentrations in a non-enzymatic way. For approx-
imately 12 h, 100 μM NAD(P)H prevents DA-100 oxidation,
acting as an intracellular antioxidant. Although NAD(P)H is not
usually considered to be a directly operating antioxidant, it has
been demonstrated that NAD(P)H is a decisive antioxidant
compound of major importance in mitochondria compartment
[31]. The following sequence of reactions can be deduced from
our data and the redox potentials:
DA+O2↔DAox (indicating different forms of DA-oxidized
compounds),
NAD(P)H+ DAox↔NAD(P)++DA.
NAD(P)H oxidizes in the presence of oxidized DA
(dopaminequinone, DAchr), thereby regenerating reduced DA
in a cycle that depletes the cell of NADH and NADPH (Fig. 10),
until NAD(P)H concentration decreases and DA autoxidation
may proceed freely. By this mechanism DA could act as an
antioxidant, but oxidized DAwould be responsible for the loss
of NAD(P)H and, hence, of reductive power. The death
program in which cytoplasmic and mitochondrial structures
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mitochondria function is sufficiently preserved so as not to
start an apoptotic program, the NADPH decrease in the
cytoplasm may lead to autophagy [21], as in starvation. The
two mechanisms are not mutually exclusive [30] and a recent
study demonstrated that inhibition of autophagy leads to
apoptosis [13].
These results strongly support the view that cells accumulat-
ing DA, mainly dopaminergic neurons of the nigrostriatal
pathway, are at high risk when antioxidant systems or any
mechanism preventing DA increase in cytoplasm (e.g. vesicular
amine transporters) decay. Earlier studies suggested that a toxic
effect of intracellular DA not linked to its oxidation cannot be
excluded [45,57]. However, the process described here could be
sufficient to explain the loss of ATP and ionic homeostasis
leading to cell death. Different effects on protein activation and
expression have been described as caused byDA, involving p38,
c-Jun, C/EBPß, GADD153, p53 or α-synuclein [22,38,47]. All
these effects are blocked by antioxidants, and may thus have
their origin in DA oxidation. In conclusion, the oxidation of DA
leads to a decrease in [NADH]/[NAD+] and [NADPH]/
[NADP+] ratios and, therefore, to the loss of the reductive
capacity of the cell, and this mechanism is sufficient to explain
DA toxicity.
Acknowledgments
We are grateful to all the members of the Biochemistry
Department (Bellvitge Campus) of the University of Barcelona,
especially Dr. J.C. Perales and Dr. J. Bermúdez for their helpful
suggestions and to Científic-Tècnic service of the UB-Bellvitge.
We would also like to thank Robin Rycroft for helping with the
English manuscript. The study was supported by grants from
the Spanish Government, BFI 2003-02883, BFI 2003-02539,
and from the Fundació La Marató-TV3 (010310).
References
[1] J.D. Adams, L.K. Klaidman, M.L. Chang, J. Yang, Brain oxidative stress-
analytical chemistry and thermodynamics of glutathione and NADPH,
Curr. Top. Med. Chem. 1 (2001) 473–482.
[2] P. Anglade, S. Vyas, F. Javoy-Agid, M.T. Herrero, P.P. Michel, J. Márquez,
A. Mouatt-Prigent, M. Ruberg, E.C. Hirsch, Y. Agid, Apoptosis and
autophagy in nigral neurons of patients with Parkinson's disease, Histol.
Histopathol. 12 (1997) 25–31.
[3] P. Aroca, F. Solano, J.C. García-Borrón, J.A. Lozano, A new spectropho-
tometric assay for dopachrome tautomerase, J. Biochem. Biophys.
Methods 21 (1990) 35–46.
[4] J.T. Barron, M.F. Sasse, A. Nair, Effect of angiotensin II on energetics,
glucose metabolism and cytosolic NADH/NAD and NADPH/NADP redox
in vascular smooth muscle, Mol. Cell. Biochem. 262 (2004) 91–99.
[5] A. Barzilai, E. Melamed, A. Shirvan, Is there a rationale for neuroprotec-
tion against dopamine toxicity in Parkinson's disease? Cell Mol.
Neurobiol. 21 (2001) 215–235.
[6] D. Ben-Shachar, R. Zuk, H. Gazawi, P. Ljubuncic, Dopamine toxicity
involves mitochondria complex I inhibition: implications to dopamine-related
neuropsychiatric disorders, Biochem. Pharmacol. 67 (2004) 1965–1974.
[7] D. Berg, M.B.H. Youdim, P. Riederer, Redox imbalance, Cell Tissue Res.
318 (2004) 201–213.
[8] S.B. Berman, T.G. Hastings, Dopamine oxidation alters mitochondriarespiration and induces permeability transition in brain mitochondria:
implications for Parkinson's disease, J. Neurochem. 73 (1999) 1127–1137.
[9] M.V. Berridge, A.S. Tan, Characterization of the cellular reduction of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT):
subcellular localization, substrate dependence, and involvement of
mitochondrial electron transport in MTT reduction, Arch. Biochem.
Biophys. 303 (1993) 474–482.
[10] M.N. Berry, The function of energy-dependent redox reactions in cell
metabolism, FEBS Lett. 117S (1980) K106–K120.
[11] D. Blum, S. Torch, N. Lamberg, M.F. Nissou, A.L. Benabid, R. Sadoul,
J.M. Verna, Molecular pathways involved in the neurotoxicity of 6-
OHDA, dopamine and MPTP: contribution to the apoptotic theory in
Parkinson's disease, Prog. Neurobiol. 65 (2001) 135–172.
[12] J. Boada, B. Cutillas, T. Roig, J. Bermúdez, S. Ambrosio, MPP+-induced
dysfunction is potentiated by dopamine, Biochem. Biophys. Res.
Commun. 268 (2000) 916–920.
[13] P. Boya, R.A. González-Polo, N. Casares, J.L. Perfettini, P. Dessen, N.
Larochette, D. Métivier, D. Meley, S. Souquere, T. Yoshimori, G. Pierron,
P. Codogno, G. Kroemer, Inhibition of macroautophagy triggers apoptosis,
Mol. Cell. Biol. 25 (2005) 1025–1040.
[14] M.V. Clement, L.H. Long, J. Ramalingam, B. Halliwell, The cytotoxicity
of dopamine may be an artefact of cell culture, J. Neurochem. 81 (2002)
414–421.
[15] G. Einsenhofer, I.J. Kopin, D.S. Goldstein, Catecholamine metabolism: a
contemporary view with implications for physiology and medicine,
Pharmacol. Rev. 56 (2004) 331–349.
[16] C. Fang, X. Tang, X. Zhou, Preparation of poly(malachite green) modified
electrode and the determination of dopamine and ascorbic acid, Anal. Sci.
15 (1999) 41–46.
[17] H. Fedorow, F. Tribl, G. Halliday, M. Gerlach, P. Riederer, K.L. Double,
Neuromelanin in human dopamine neurons: comparison with peripheral
melanins and relevance to Parkinson's disease, Progr. Neurobiol. 75
(2005) 109–124.
[18] C.J. Fowler, K.F. Tipton, Concentration dependence of the oxidation of
tyramine by the two forms of rat liver mitochondrial monoamine oxidase,
Biochem. Pharmacol. 30 (1981) 3329–3332.
[19] M.R. Gluck, G.D. Zeevalk, Inhibition of brain mitochondria respiration by
dopamine and its metabolites: implications for Parkinson's disease and
catecholamines-associated diseases, J. Neurochem. 91 (2004) 788–795.
[20] N. Gómez, M. Unzeta, K. Tipton, M. Anderson, A.M. O'Carroll,
Determination of monoamine oxidase concentrations in rat liver by
inhibitor binding, Biochem. Pharmacol. 35 (1986) 4467–4472.
[21] C. Gómez-Santos, I. Ferrer, A.F. Santidrián, M. Barrachina, J. Gil, S.
Ambrosio, Dopamine induces autophagic cell death and α-synuclein
increase in human neuroblastoma SH-SY5Y cells, J. Neurosci. Res. 73
(2003) 341–350.
[22] C. Gómez-Santos, M. Barrachina, P. Giménez-Xavier, E. Dalfó, I. Ferrer,
S. Ambrosio, Induction of C/EBPß and GADD153 expression by
dopamine in human neuroblastoma cells, Brain Res. Bull. 65 (2005)
87–95.
[23] M.E. Haque, M. Asanuma, Y. Higashi, I. Miyazaki, K-I. Tanaka, N.
Ogawa, Apoptosis-inducing neurotoxicity of dopamine and its metabolites
via reactive generation in neuroblastoma cells, Biochem. Biophys. Acta
1619 (2003) 39–52.
[24] J. Hirrlinger, J.B. Schulz, R. Dringen, Effects of dopamine on the
glutathione metabolism of cultured astroglial cells: implications for
Parkinson's disease, J. Neurochem. 82 (2002) 458–467.
[25] H.J. Hohorst, in: H.U. Bergmeyer (Ed.), Methods of Enzymatic Analysis,
Academic Press, New York, 1993, pp. 266–270.
[26] K.R. Hoyt, I.J. Reynolds, T.G. Hasting, Mechanisms of dopamine-induced
cell death in cultured rat forebrain neurons: interactions with and
differences from glutamate-induced cell death, Exp. Neurol. 143 (1997)
269–281.
[27] Y. Izumi, H. Sawada, N. Yamamoto, T. Kume, H. Katsuki, S. Shimohama,
A. Akaike, Iron accelerates the conversion of dopamine-oxidized
intermediates into melanin and provides protection in SH-SY5Y cells,
J. Neurosci. Res. 82 (2005) 126–137.
[28] H. Jiang, Q. Jiang, J. Feng, Parkin increases dopamine uptake by
574 P. Giménez-Xavier et al. / Biochimica et Biophysica Acta 1762 (2006) 564–574enhancing the cell surface expression of dopamine transporter, J. Biol.
Chem. 279 (2004) 54380–54386.
[29] D.C. Jones, P.G. Gunasekar, J.L. Borowitz, G.E. Isorm, Dopamine-
induced apoptosis is mediated by oxidative stress and is enhanced by
cyanide in differentiated PC12 cells, J. Neurochem. 74 (2000) 2296–2304.
[30] E. Junn, M.M. Mouradian, Apoptotic signaling in dopamine-induced cell
death: the role of oxidative stress, p38 mitogen-activated protein kinase,
cytochrome c and caspases, J. Neurochem. 78 (2001) 374–383.
[31] M. Kirsch, H. De Groot, NAD(P)H, a directly operating antioxidant?
FASEB J. 15 (2001) 1569–1574.
[32] I.J. Kopin, Neurotransmitters and disorders of the basal ganglia, in: G.J.
Siegel, B.W. Agranoff, R.W. Albers, P.B. Molinoff (Eds.), Basic
Neurochemistry, Raven Press, New York, 1993, p. 903.
[33] C.T. Lai, P.H. Yu, Dopamine and l-ß-3,4-dihydroxyphenylalanine
hydrochloride (L-dopa)-induced cytotoxicity towards catecholaminergic
neuroblastoma SH-SY5Y cells, Biochem. Pharmacol. 53 (1997) 363–372.
[34] C.T. Lai, P.H. Yu, R(−)-deprenyl potentiates dopamine-induced cytotoxi-
city toward catecholaminergic neuroblastoma SH-SY5Y cells, Toxicol.
Appl. Pharmacol. 142 (1997) 186–191.
[35] M.J. LaVoie, T.G. Hastings, Dopamine quinone formation and protein
modification associated with the striatal neurotoxicity of methamphet-
amine: evidence against a role for extracellular dopamine, J. Neurosci. 19
(1999) 1484–1491.
[36] C.S. Lee, J.H. Han, Y.Y. Jang, J.H. Song, E.S. Han, Differential effect of
catecholamines and MPP+ on membrane permeability in brain
mitochondria and cell viability in PC12 cells, Neurochem. Int. 40
(2002) 361–369.
[37] N. Lode, G. Bruchelt, G. Seitz, S. Gebhardt, V. Gekeler, D. Niethammer, J.
Beck, Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis
of monoamine transporters in neuroblastoma cell lines: correlations to
meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene
expression, Eur. J. Cancer 31A (1995) 586–590.
[38] Y. Luo, G.C. Kokkonen, A. Hattori, F.J. Chrest, G.S. Roth, Dopamine
stimulates redox-tyrosine kinase signaling and p38 MAPK in activation of
astrocytic C6-D2L cells, Brain Res. 850 (1999) 21–38.
[39] B.A. Mclaughlin, D. Nelson, M. Erecinska, M. Chesselet, Toxicity of
dopamine to striatal neurons in vitro and potentiation of cell death by a
mitochondria inhibitor, J. Neurochem. 70 (1990) 428–435.
[40] M.A.Mena, J. García de Yébenes, A. Dwark, S. Fahn, N. Latov, J. Herbert,
E. Flaster, D. Slonim, Biochemical properties of monoamine-rich human
neuroblastoma cells, Brain Res. 486 (1989) 286–296.
[41] P.P. Michel, F. Hefti, Toxicity of 6-hydroxydopamine and dopamine for
dopaminergic neurons in culture, J. Neurosci. Res. 26 (1990) 428–435.
[42] N. Morikawa, Y. Nakagawa-Hattori, Y. Mizuno, Effect of dopamine,
dimethoxyphenylethylamine, papaverine, and related compounds on
mitochondria respiration and complex I activity, J. Neurochem. 66
(1996) 1174–1181.
[43] D. Offen, S. Gorodin, E. Melamed, J. Hanania, Z. Malik, Dopamine-
melanin is actively phagocytized by PC12 cells and cerebellar granular
cells: possible implications for the etiology of Parkinson's disease,
Neurosci. Lett. 260 (1999) 101–104.
[44] S. Pålham, A.I. Ruusala, L. Abrahamsson, M.E.K. Mattson, T. Esscher,
Retinoic acid-induced differentiation of cultured human neuroblastoma
cells: a comparison with phorbol ester-induced differentiation, Cell Differ.
14 (1984) 135–144.
[45] R. Pedrosa, P. Soares-da-Silva, Oxidative and non-oxidative mechanisms of
neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-
DOPA) and dopamine, Br. J. Pharmacol. 137 (2002) 1305–1313.
[46] C. Pifl, J. Zezula, A. Spittler, A. Kattinger, H. Reither, M.G. Caron, O.
Hornykiewicz, Antiproliferative action of dopamine and norepinephrine inneuroblastoma cells expressing the human dopamine transporter, FASEB
J. 15 (2001) 1607–1610.
[47] S. Porat, R. Simantov, Bcl-e and p53: role in dopamine-induced apoptosis
and differentiation, Ann. N.Y. Acad. Sci. 893 (1999) 372–375.
[48] M.L. Richards, W. Sadee, Human neuroblastoma cell lines as models of
catechol uptake, Brain Res. 384 (1986) 132–137.
[49] M. Santiago, A. Machado, J. Cano, Nigral and striatal comparative study
of the neurotoxic action of 1-methyl-4-phenylpyridinium ion: involvement
of dopamine uptake system, J. Neurochem. 66 (1996) 1182–1190.
[50] G. Seitz, H.B. Stegmann, H.H. Jager, H.M. Schlude, H. Wolburg, V.A.
Roginsky, D. Niethammer, Neuroblastoma cells expressing the noradren-
aline transporter are destroyed more selectively by 6-fluorodopamine than
by 6-hydroxydopamine, J. Neurochem. 75 (2000) 511–520.
[51] A.P. Senft, T.P. Dalton, H.G. Shertzer, Determining glutathione and
glutathione disulfide using the fluorescence probe o-phthalaldeyde, Anal.
Biochem. 280 (2000) 80–86.
[52] X.-M. Shen, G. Dryhurst, Further insights into the influence of L-
cysteine on the oxidation chemistry of dopamine: reaction pathways of
potential relevance to Parkinson's disease, Chem. Res. Toxicol. 9 (1996)
751–763.
[53] E. Sofic, N. Denisova, K. Youdim, V. Vatrejak-Velagic, C. De Filippo,
A. Mehmedagic, A. Causevic, G. Cao, J.A. Joseph, R.L. Prior,
Antioxidant and pro-oxidant capacity of catecholamines and related
compounds, J. Neural Transm. 108 (2001) 541–557.
[54] J.P.E. Spencer, A. Jenner, O.A. Aruoma, P.J. Evans, H. Kaur, D.T. Dexter,
P. Jenner, A.J. Lees, D.C. Marsden, B. Halliwell, Intense oxidative DNA
damage promoted by L-dopa and its metabolites. Implications for
neurodegenerative disease, FEBS Lett. 353 (1994) 246–250.
[55] D. Sulzer, J. Bogulavsky, K.E. Larsen, G. Behr, E. Karatekin, M.H.
Kleinman, N. Turro, D. Krantz, R.H. Edwards, L.A. Greene, L. Zecca,
Neuromelanin biosynthesis is driven by excess cytosolic catecholamines
not accumulated by synaptic vesicles, Proc. Natl. Acad. Sci. U. S. A. 97
(2000) 11869–11874.
[56] O. Weinreb, S. Mandel, M.B.H. Youdim, cDNA gene expression
profile homology of antioxidants and their antiapoptotic and
proapoptotic activities in human neuroblastoma cells, FASEB J.
(2003). doi: 10.1096/fj.02-0712fje.
[57] P. Weingarten, J. Bermak, Q.Y. Zhou, Evidence for non-oxidative
dopamine cytotoxicity: potent activation of NF-kappa B and lack of
protection by anti-oxidants, J. Neurochem. 76 (2001) 1794–1804.
[58] A.R. West, S.B. Floresco, A. Charara, J.A. Rosenkranz, Electrophysio-
logical interaction between striatal glutamatergic and dopaminergic
systems, Ann. N.Y. Acad. Sci. 1003 (2003) 53–74.
[59] H. Yi, W. Maruyama, Y. Akao, T. Takahashi, K. Iwasa, M.B.H. Youdim,
M. Naoi, N-Propargylamine protects SH-SY5Y cells from apoptosis
induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through
stabilization of mitochondria membrane and induction of anti-apoptotic
Bcl-2, J. Neural Transm. (2005). doi: 10.1007/s00702-005-0299-z.
[60] L. Zecca, A. Stroppolo, A. Gatti, D. Tampellini, M. Toscani, M. Gallorini,
G. Giaveri, P. Arosio, P. Santambrogio, R.G. Fariello, E. Karatekin, M.H.
Kleinman, N. Turro, O. Hornykiewicz, F.A. Zucca, The role of iron and
copper molecules in the neuronal vulnerability of locus coeruleus and
substantia nigra during aging, Proc. Natl. Acad. Sci. U. S. A. 26 (2004)
9843–9848.
[61] R. Zilkha-Falb, I. Ziv, N. Nardi, D. Offen, E. Melamed, A. Barzilai,
Monoamine-induced apoptotic neuronal cell death, Cell. Mol. Neurobiol.
17 (1997) 101–118.
[62] F. Zoccorato, P. Toscano, A. Alexandre, Dopamine-derived dopamino-
chrome promotes H2O2 release at mitochondria complex I, J. Biol. Chem.
280 (2005) 15587–15594.
